TOp TEn resistant Microorganisms at intensive care unit: a 2018 global expert survey (TOTEM study protocol) by Rello, Jordi et al.
Page 1 of 4
© Journal of Emergency and Critical Care Medicine. All rights reserved. J Emerg Crit Care Med 2018;2:6jeccm.amegroups.com
Introduction
Multidrug-resistant (MDR) and extreme drug-resistant 
(XDR) bacteria have become a health priority in many 
national health systems, with a high burden of disease 
and uprising costs for attention (1,2). Many efforts have 
been made to prevent colonization, infection and decrease 
mortality, mostly in critically ill patients (3-7). However, 
differences regarding geographical zones, accessibility 
to new treatments, and differences between public and 
private health systems have been overlooked, along with 
the controversies between local and societies guidelines; 
some including poor quality of the evidence base, variety 
on aims and differences in methodology, MDR definitions 
and prevention measures (8,9). Nevertheless, guidelines 
implementation is challenging especially where resources 
are limited. For these reasons, it is urgent to know based on 
a clinical base experience, which are the ten most important 
MDR bacteria, based on clinical presentation, severity-of-
illness, impact on outcomes and resources utilization. 
Recently a global priority list (PPL) of MDR bacteria 
was proposed to guide research, discovery and development 
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of new antibiotics by the World Health Organization 
(WHO) (10), however critically ill patients who represents 
the group where these pathogens becomes an urgent threat, 
because of the imperativeness in taking decisions, have been 
mixed with other types of patients. To know which are the 
more representative’s pathogens involved in MDR infections 
in critically ill patients and the possibility to ranked them is 
crucial to guide production of guidelines and future clinical 
research. With this background and due to imbalances in 
representation in previous priority lists, we developed the 
TOp TEn resistant Microorganisms (TOTEM) in critical 
care study group to assess this urgent matter.
The main objective of the TOTEM study is to describe 
assessed on expert opinion and current evidence a global 
list of the top ten most clinically relevant MDR/XDR 
bacteria involved in critically ill patients around the world. 
Secondary objectives are to prioritize them into three 
different groups: critical, high, medium according to its 
urgency of prevention, detection and development of new 
treatment strategies in a global basis, identify whether 
geographical location significantly influence presence of 
one or another MDR bacteria. This would be helpful in 
addressing unmet clinical needs and a research agenda, with 
special emphasis on respiratory infections and bacteremia 
causing severe acute respiratory failure, sepsis and septic 
shock.
Methods
Based on recent recommendations (11,12) TOTEM survey 
was designed. A coordination steering committee of experts 
all involved in identification, prevention and treatment 
of MDR bacteria in critically ill patients will be selected, 
based on publications, background, geographical region 
and recommendations, and constitutes the TOTEM study 
group. An electronic survey will be created in concordance 
with the steering committee. The list of organisms will 
be based in next criteria for prioritization: all-cause 
mortality, healthcare and community burden, prevalence of 
resistance, 5-year trend of resistance, transmissibility and 
preventability, severity-of-illness, treatability and current 
pipeline. 
The survey will be performed using an electronic 
platform (SurveyMonkey®). This survey will be distributed 
by invitation from the members of the Steering Committee; 
it will be an online questionnaire requiring no specific 
data of patients, no intervention and no informed consent 
is required. Due to the observational aim of the study, 
qualifying as quality control assessment, research ethics 
board consultation was exempted.
In order to develop a more realistic understanding of 
clinical practice, we encouraged all clinicians that care for 
critically ill patients, with interest and experience on critical 
infectious diseases to response to the survey. Paediatric 
and neonatal intensive care units (ICUs) are excluded. It 
is requested that only one professional per unit complete 
the questionnaire, to have consistency and to avoid data 
multiplication. Data analyses and reports will be done with 
anonymization of respondents. An estimated of at least 60% 
of answers is expected. The main deliverable will be a PPL 
of resistant pathogens representing a threat for ICU adults. 
Regional secondary analyses will be performed.
Questionnaire
The survey will compile data on key aspects of the actual 
threat of antimicrobial-resistant bacteria globally in the 
ICU. Details of the survey are summarized in Appendix 1. 
Definitions
Definition of “Resistant” organisms will be based on 
breakpoints provided by EUCAST recommendations (13). 
MDR: bacteria non-susceptibility to at least one agent 
in three or more antimicrobial categories: resistant to 
ceftazidime, cefepime, aztreonam, ciprofloxacin, piperacillin, 
and gentamicin. XDR: non-susceptibility to at least one 
agent in all but two or fewer antimicrobial categories (14). 
Cohorting measures: patients requiring transmission basic 
precautions (patients with the same single infectious agent) 
are placed within an area of a hospital ward with a dedicated 
team of healthcare staff. Formulary restriction is defined 
as the need of an infection control team authorization for 
specific antibiotic prescription (broad spectrum antibiotics). 
Cycling antibiotics: scheduled substitution of a class of 
antibiotics (or a specific member of a class) with a different 
class (or a specific member of that class) that exhibits a 
comparable spectrum of activity. 
Statistical analysis
All responses to survey questions are categorical variables 
and will be analyzed by using descriptive statistics, reporting 
proportions (percentages). Chi-square test (or Fisher’s 
exact test when appropriate) will be performed to evaluate 
a potential association between the geographical location 
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of the participants and responses to survey questions (15). 
A two-tailed P value less than 0.05 will be considered 
statistically significant. In order to evaluate the presence of 
difference in practices according to geographical location 
and health care system; multivariable analysis to test the 
independent effect of variables on the outcome of interest 
will be performed. Specific data according to techniques 
used to determine resistance is out of the scope of this study.
Aim
To know from first-hand the most important resistant 
pathogens in participating ICUs. To analyze globally and 
regionally most clinically important resistant pathogens 
according to answers given by attending physicians. To 
rank from critical to medium urgency the list of MDR 
bacteria in participating ICUs. To assess knowledge on 
preventability measures taken into account. Finally, some 
recommendations where future efforts should be directed in 
prevention, adequate treatment and clinical trials regarding 
MDR infections in critically ill patients can be proposed.
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Appendix 1
*These details are only to identify duplicates. Data collection, analysis and report will be anonymised.
Contact details
1. Name/initials of the person answering the questionnaire*:
2. E-mail:
3. Name of the unit:
4. Name of the hospital:
5. Private/public:
6. Academic-training/non-academic:
7. City/rural:
8. Country/province:
Professional information
9. Do you belong to any of these societies?
A) ESCMID.
B) ESICM.
C) ATS/IDSA.
D) National Society of Critical Care (name).
E) Panamerican Society of Infectious Diseases.
10. Primary specialty: 
A) Internal medicine.
B) Anaesthesiology.
C) Emergency medicine.
D) Surgery.
E) Infectious disease.
F) Clinical pharmacology.
G) Microbiology.
H) Preventive medicine and epidemiology/public 
health.
I) Intensive care medicine.
11. Name your ICU sub-specialty:
A) Trauma.
B) Cardiac surgery.
C) Medical-surgical.
D) Other.
13. Does your unit admit >5%:
A) Transplant patients (   ).
B) Haematological patients (   ).
C) Burn patients (   ).
D) No immunocompromised patients (   ).
13.  Number of beds in your ICU: ___
14. Nurse/HCP ratio: in your ICU: __/__
15. Experience in ICU infections: 
A) 1–5 years.
B) 5–10 years.
C) >10 years.
TOTEM indicators
16. In the last 5 years have you noticed an increase in 
community-acquired infections due to MDR bacteria 
admitted to your ICU? 
A) Yes.
B) No.
17. In the last 5 years have you noticed an increase in MDR 
bacteria on hospital-acquired infections admitted to 
your ICU?
A) Yes.
B) No.
18. In your experience are resistant infections associated 
with higher mortality non-resistant ones? 
A) Yes.
B) No.
19. If your answer was Yes; is it because: 
A) Resistant pathogens are more virulent. 
B) Correct initial treatment is more difficult. 
C) More severely ill patients develop resistant 
infections.
D) None of the above.
E) All of the above.
20. When a resistant pathogen is detected in your ICU; are 
prevention measures implemented (as indicated in your 
local/national guidelines)? 
A) Yes, almost always.
B) Yes, sometimes.
C) No.
21. Specify witch pathogen is the main concern in your unit 
(mark only one):
A) Carbapenemase expressing Klebsiella pneumoniae 
(KPC) (   ).
B) Carbapenem-resistant Acinetobacter baumannii (   ).
C) Carbapenem-resistant Pseudomonas aeruginosa (   ).
D) Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) (   ).
E) Extended-spectrum beta-lactamase producing 
Enterobacteriaceae (ESBL).
22. According to your previously answer, which of the 
following are taken into (you can mark more than one).
A) Contact restriction measures (   ).
B) Air restriction measures/negative pressure rooms (   ).
C) Enhanced hand wash measures (   ).
D) Cultures from possible carriage sites (   ). 
E) Notify Epidemiologist and/or Nosocomial 
infections committee (   ).
F) Educational measures to staff, nurses, fellows/
junior doctors, students, etc. (   ).
G) Isolation / cohort measures (   ).
23. In your experience, please rank from 1 to 5 (1: most 
urgent; 5: less urgent) the measures that could limit the 
development and spread of antibiotic resistance: 
 Cohort __
 Increase nurse/HCP ratio __
 Infectious diseases/epidemiology/other inter-
consultation __
 Formulary restriction __
 De-escalation __
24. In your experience, which measures do you believe are 
most effective in preventing MDR development and 
spread (rank 1 to 5) 
 Antibiotic de-escalation: __
 Cycling of antibiotics: __
 Education programs: __
 Formulary restriction: __
 Infectious disease consultation: __
25. Please rank from 1 to 5 (1: most concern; 5: less 
concern) regarding your level of concern for emerging 
resistance to the following groups of antibiotics:
 Quinolones: __
 3rd or 4th generation Cephalosporins: __
 Carbapenems: __
 Beta lactam inhibitors (pip/taz): __
 Glycopeptides: __
26. Please order from 1 to 10 (1: most common; 10: 
less common) according to prevalence of isolated 
pathogens) in your ICU in 2017 (patients with a 
confirmed infection):
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
 Vancomycin-resistant Enterococci (VRE) __
 Extended spectrum beta-lactamases (ESBL) 
Klebsiella pneumoniae __
 Extended spectrum beta-lactamases (ESBL) 
Escherichia coli __
 XDR Pseudomonas aeruginosa __
 Carbapenem-resistant Pseudomonas aeruginosa __
 Carbapenem-resistant Acinetobacter baumannii __ 
 Carbapenem-resistant Klebsiella pneumoniae __
 Trimethoprim-sulfamethoxazole/septrin (TMP-
SMX)-resistant Stenotrophomonas maltophilia __
 AmpC hyperproductor Enterobacteriaceae __
27. Locally, in your unit, are there any other resistant 
microorganism you believe due to frequency, mortality 
or difficulties in adequate initial treatment should be 
included in list? 
A) Yes.
B) No.
28. If previous answer was affirmative, please identify it: 
______________
29. Please order from 1 to 10 (1: most lethal; 10: less lethal) 
according to related mortality from your perspective in 
your ICU in the last year:
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
 Vancomycin-resistant Enterococci (VRE) __
 Extended spectrum beta-lactamases (ESBL) 
Klebsiella pneumoniae __
 Extended spectrum beta-lactamases (ESBL) 
Escherichia coli __
 Multidrug-resistant Pseudomonas aeruginosa __
 Carbapenem-resistant Pseudomonas aeruginosa __
 Carbapenem-resistant Acinetobacter baumannii __ 
 Carbapenem-resistant Klebsiella pneumoniae __
 TMP-SMX-resistant Stenotrophomonas maltophilia __
 Extended spectrum beta-lactamases (ESBL) 
Serratia spp __
30. Please order from 1 to 10 (1: most difficult, 10: less 
difficult) adequate treatment availability; from your 
perspective in your ICU in the last year:
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
 Vancomycin-resistant Enterococci (VRE) __
 Extended spectrum beta-lactamases (ESBL) 
Klebsiella pneumoniae __
 Extended spectrum beta-lactamases (ESBL) 
Escherichia coli __
 Multidrug-resistant Pseudomonas aeruginosa __
 Carbapenem-resistant Pseudomonas aeruginosa __
 Carbapenem-resistant Acinetobacter baumannii __ 
 Carbapenem-resistant Klebsiella pneumoniae __
 TMP-SMX-resistant Stenotrophomonas maltophilia __
 Extended spectrum beta-lactamases (ESBL) 
Serratia spp __
31. Regarding community-acquired pneumonia please rank 
from 1 to 5 most common resistant pathogens isolated 
in your ICU:
 3rd generation cephalosporins-resistant Streptococcus 
pneumoniae __
 Macrolide-resistant Streptococcus pneumoniae __ 
 3 rd  genera t ion  cepha lo spor in s - r e s i s t an t 
Enterobacteriaceae __
 Quinolones-resistant Pseudomonas aeruginosa __ 
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
32. Regarding hospital-acquired pneumonia (and VAP) 
please rank from 1 to 5 most common resistant 
pathogens isolated in your ICU:
 Multidrug-resistant Pseudomonas aeruginosa __ 
 Carbapenem-resistant Pseudomonas aeruginosa __
 Carbapenem-resistant Acinetobacter baumannii __
 Carbapenem-resistant Klebsiella pneumoniae __
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
33. Regarding intraabdominal infections please rank from 1 
to 5 most common resistant pathogens isolated in your 
ICU:
 Vancomycin-resistant Enterococci __
 Multidrug-resistant Pseudomonas aeruginosa __ 
 Multidrug-resistant Escherichia coli __
 Carbapenem-resistant Acinetobacter baumannii __
 Carbapenem-resistant Klebsiella pneumoniae __
34. Regarding nosocomial soft tissue and skin infections 
please rank from 1 to 5 most common resistant 
pathogens isolated in your ICU:
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
 Vancomycin-resistant Enterococci __
 Multidrug-resistant Pseudomonas aeruginosa __ 
 Multidrug-resistant Escherichia coli __
 Carbapenem-resistant Klebsiella pneumoniae __
35. Regarding nosocomial catheter-associated bacteremia 
please rank from 1 to 5 most common resistant 
pathogens isolated in your ICU:
 Oxacillin/methicillin-resistant Staphylococcus aureus 
(MRSA) __
 Vancomycin-resistant Enterococci __
 Multidrug-resistant Pseudomonas aeruginosa __ 
 Multidrug-resistant Escherichia coli __
 Carbapenem-resistant Klebsiella pneumoniae __
